Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Associations of Multiple NOTCH4 Exonic Variants with Systemic Sclerosis.

Zhou X, Li H, Guo S, Wang J, Shi C, Espitia M, Guo X, Wang Q, Liu M, Assassi S, Reveille JD, Mayes MD.

J Rheumatol. 2018 Nov 15. pii: jrheum.180094. doi: 10.3899/jrheum.180094. [Epub ahead of print]

PMID:
30442821
2.

KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.

Salazar GA, Kuwana M, Wu M, Estrada-Y-Martin RM, Ying J, Charles J, Mayes MD, Assassi S.

J Rheumatol. 2018 Aug;45(8):1153-1158. doi: 10.3899/jrheum.170518. Epub 2018 Jul 1.

PMID:
29961690
3.

The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.

Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD; SPIN Investigators.

Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631. doi: 10.1093/rheumatology/key139.

PMID:
29868924
4.

The Antifibrotic Effect of A2B Adenosine Receptor Antagonism in a Mouse Model of Dermal Fibrosis.

Karmouty-Quintana H, Molina JG, Philip K, Bellocchi C, Gudenkauf B, Wu M, Chen NY, Collum SD, Ko J, Agarwal SK, Assassi S, Zhong H, Blackburn MR, Weng T.

Arthritis Rheumatol. 2018 Oct;70(10):1673-1684. doi: 10.1002/art.40554. Epub 2018 Aug 6.

PMID:
29771006
5.

Distinguishing Molecular Features of Allergic Fungal Rhinosinusitis.

Tyler MA, Padro Dietz CJ, Russell CB, Citardi MJ, Assassi S, Ying J, Luong AU.

Otolaryngol Head Neck Surg. 2018 Jul;159(1):185-193. doi: 10.1177/0194599818764349. Epub 2018 Mar 27.

PMID:
29584543
6.

Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study.

Merz EL, Kwakkenbos L, Carrier ME, Gholizadeh S, Mills SD, Fox RS, Jewett LR, Williamson H, Harcourt D, Assassi S, Furst DE, Gottesman K, Mayes MD, Moss TP, Thombs BD, Malcarne VL; SPIN Investigators.

BMJ Open. 2018 Mar 6;8(3):e018641. doi: 10.1136/bmjopen-2017-018641.

7.

Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study.

Fox RS, Kwakkenbos L, Carrier ME, Mills SD, Gholizadeh S, Jewett LR, Roesch SC, Merz EL, Assassi S, Furst DE, Gottesman K, Mayes MD, Thombs BD, Malcarne VL; and the SPIN Investigators.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1646-1652. doi: 10.1002/acr.23532.

PMID:
29409146
8.

Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis.

Pauling JD, Salazar G, Lu H, Betteridge ZE, Assassi S, Mayes MD, McHugh NJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):712-717. doi: 10.1093/rheumatology/kex458.

PMID:
29294089
9.

Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.

Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD.

PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.

10.

Role of STAT3 in skin fibrosis and transforming growth factor beta signalling.

Pedroza M, To S, Assassi S, Wu M, Tweardy D, Agarwal SK.

Rheumatology (Oxford). 2018 Oct 1;57(10):1838-1850. doi: 10.1093/rheumatology/kex347.

PMID:
29029263
11.

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, Matucci-Cerinic M, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE.

Scand J Rheumatol. 2018 Jan;47(1):62-70. doi: 10.1080/03009742.2017.1299793. Epub 2017 Oct 9.

PMID:
28990485
12.

Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups.

Jamalyaria F, Ward MM, Assassi S, Learch TJ, Lee M, Gensler LS, Brown MA, Diekman L, Tahanan A, Rahbar MH, Weisman MH, Reveille JD.

Clin Rheumatol. 2017 Oct;36(10):2359-2364. doi: 10.1007/s10067-017-3767-6. Epub 2017 Aug 6.

13.

Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS™ trial investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.

14.

CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.

Wu M, Baron M, Pedroza C, Salazar GA, Ying J, Charles J, Agarwal SK, Hudson M, Pope J, Zhou X, Reveille JD, Fritzler MJ, Mayes MD, Assassi S.

Arthritis Rheumatol. 2017 Sep;69(9):1871-1878. doi: 10.1002/art.40171. Epub 2017 Aug 8.

15.

Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis.

Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada-Y-Martin R, Pedroza C, Mills TW, Walker J, Baron M, Stevens W, Proudman SM, Nikpour M, Mehra S, Wang M, Fritzler MJ; Canadian Scleroderma Research Group; Australian Scleroderma Cohort Study; Genetics versus Environment in Scleroderma Outcome Study.

J Rheumatol. 2017 Jun;44(6):799-805. doi: 10.3899/jrheum.160574. Epub 2017 Apr 1.

16.

Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort.

Gordon JK, Girish G, Berrocal VJ, Zhang M, Hatzis C, Assassi S, Bernstein EJ, Domsic RT, Hant FN, Hinchcliff M, Schiopu E, Steen VD, Frech TM, Khanna D.

J Rheumatol. 2017 Jun;44(6):791-794. doi: 10.3899/jrheum.160654. Epub 2017 Mar 15.

17.

Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.

López-Isac E, Bossini-Castillo L, Palma AB, Assassi S, Mayes MD, Simeón CP, Ortego-Centeno N, Vicente E, Tolosa C, Rubio-Rivas M, Román-Ivorra JA, Beretta L, Moroncini G, Hunzelmann N, Distler JHW, Riemekasten G, de Vries-Bouwstra J, Voskuyl AE, Radstake TRDJ, Herrick A, Denton CP, Fonseca C, Martín J.

Arthritis Rheumatol. 2017 Jun;69(6):1337-1338. doi: 10.1002/art.40058. Epub 2017 May 9. No abstract available.

18.

Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort.

Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Harcourt D, Rumsey N, Mayes MD, Assassi S, Körner A, Fox RS, Gholizadeh S, Mills SD, Fortune C, Thombs BD; SPIN Investigators.

Body Image. 2017 Mar;20:99-106. doi: 10.1016/j.bodyim.2016.11.007. Epub 2017 Jan 6.

PMID:
28068643
19.

Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.

Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S.

Arthritis Res Ther. 2016 Dec 30;18(1):305. doi: 10.1186/s13075-016-1203-y.

20.

Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.

Lofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, Cheung P, Kuo A, Valenzuela A, Haemel A, Wolters PJ, Gordon J, Spiera R, Assassi S, Boin F, Chung L, Fiorentino D, Utz PJ, Whitfield ML, Khatri P.

JCI Insight. 2016 Dec 22;1(21):e89073. doi: 10.1172/jci.insight.89073.

21.

Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes.

Tyler MA, Russell CB, Smith DE, Rottman JB, Padro Dietz CJ, Hu X, Citardi MJ, Fakhri S, Assassi S, Luong A.

J Allergy Clin Immunol. 2017 Mar;139(3):1061-1064.e4. doi: 10.1016/j.jaci.2016.09.048. Epub 2016 Nov 18. No abstract available.

22.

Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study.

Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Bartlett SJ, Furst DE, Gottesman K, Mayes MD, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, Molnar JC, Rice DB, Thombs BD; and the SPIN Investigators.

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):92-99. Epub 2016 Aug 1.

PMID:
27494308
23.

Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations.

Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS).

Medicine (Baltimore). 2016 Aug;95(35):e4713. doi: 10.1097/MD.0000000000004713.

24.

Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic Sclerosis.

Nandiwada SL, Peterson LK, Mayes MD, Jaskowski TD, Malmberg E, Assassi S, Satoh M, Tebo AE.

J Rheumatol. 2016 Oct;43(10):1816-1824. Epub 2016 Aug 1.

PMID:
27481902
25.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators.

Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.

26.

Longitudinal patterns of pain in patients with diffuse and limited systemic sclerosis: integrating medical, psychological, and social characteristics.

Merz EL, Malcarne VL, Roesch SC, Nair DK, Salazar G, Assassi S, Mayes MD.

Qual Life Res. 2017 Jan;26(1):85-94. doi: 10.1007/s11136-016-1370-y. Epub 2016 Jul 28.

27.

Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies.

López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ; Spanish Scleroderma Group, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JH, Riekemasten G, van der Helm-van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg Ø, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Worthington J, Mayes MD, Martín J.

Arthritis Rheumatol. 2016 Sep;68(9):2338-44. doi: 10.1002/art.39730.

28.

Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer.

Assassi S.

BMJ. 2016 Jan 28;352:i472. doi: 10.1136/bmj.i472. No abstract available.

PMID:
26822198
29.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Rheumatol. 2016 Feb;68(2):299-311. doi: 10.1002/art.39501.

30.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):167-78. doi: 10.1002/acr.22804.

31.

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients.

Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD.

Arthritis Res Ther. 2016 Jan 20;18:20. doi: 10.1186/s13075-016-0923-3.

32.

The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients.

Lenna S, Assassi S, Farina GA, Mantero JC, Scorza R, Lafyatis R, Farber HW, Trojanowska M.

Arthritis Res Ther. 2015 Dec 16;17:363. doi: 10.1186/s13075-015-0881-1.

33.

Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Mohan C, Assassi S.

BMJ. 2015 Nov 26;351:h5079. doi: 10.1136/bmj.h5079. Review.

PMID:
26612523
34.
35.

Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls.

Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, McMillan JD, Horneff G, Assassi S, Charles J, Salazar G, Mayes MD, Silverman ED, Klien-Gitelman M, Lee T, Brunner HI, Reed AM, Fritzler MJ.

J Rheumatol. 2015 Dec;42(12):2419-26. doi: 10.3899/jrheum.150567. Epub 2015 Oct 15.

PMID:
26472409
36.

Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.

López-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, García de la Peña P; Spanish Scleroderma Group, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Herrick A, Worthington J, Denton CP, Fonseca C, Radstake TR, Mayes MD, Martín J.

Ann Rheum Dis. 2016 Aug;75(8):1521-6. doi: 10.1136/annrheumdis-2015-208154. Epub 2015 Sep 2.

37.

Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects.

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Baron M, Fritzler MJ.

Autoimmunity. 2015;48(8):542-51. doi: 10.3109/08916934.2015.1077231. Epub 2015 Aug 31.

PMID:
26334795
38.

Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival.

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Cohort Study (ASCS); Genetics versus Environment in Scleroderma Outcome Study (GENISOS).

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S131-5. Epub 2015 Aug 27.

PMID:
26315678
39.

Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis.

Assassi S, Swindell WR, Wu M, Tan FD, Khanna D, Furst DE, Tashkin DP, Jahan-Tigh RR, Mayes MD, Gudjonsson JE, Chang JT.

Arthritis Rheumatol. 2015 Nov;67(11):3016-26. doi: 10.1002/art.39289.

40.

Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report.

Frech TM, Revelo MP, Ryan JJ, Shah AA, Gordon J, Domsic R, Hant F, Assassi S, Shanmugam VK, Hinchcliff M, Steen V, Khanna D, Bernstein EJ, Cox J, Luem N, Drakos S.

J Med Case Rep. 2015 Jun 10;9:136. doi: 10.1186/s13256-015-0587-7.

41.

Anti-RNA Polymerase II Antibodies in a U.S. Cohort of Systemic Sclerosis Patients: Comment on the Article by Hamaguchi et al.

Patel V, Assassi S, Mayes MD, Feghali-Bostwick CA.

Arthritis Rheumatol. 2015 Sep;67(9):2547-8. doi: 10.1002/art.39203. No abstract available.

42.

Antinuclear antibody-negative systemic sclerosis.

Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD.

Semin Arthritis Rheum. 2015 Jun;44(6):680-6. doi: 10.1016/j.semarthrit.2014.11.006. Epub 2014 Nov 28.

43.

Reply: To PMID 24782356.

Assassi S.

Arthritis Rheumatol. 2015 Feb;67(2):587. doi: 10.1002/art.38946. No abstract available.

44.

Lack of Association of the CD247 SNP rs2056626 with Systemic Sclerosis in Han Chinese.

Wang J, Yi L, Guo X, He D, Li H, Guo G, Wang Y, Zou H, Gu Y, Tu W, Wu W, Yang L, Xiao R, Lai S, Assassi S, Mayes MD, Zhou X.

Open Rheumatol J. 2014 Oct 2;8:43-5. doi: 10.2174/1874312901408010043. eCollection 2014.

45.

Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus.

López-Isac E, Bossini-Castillo L, Guerra SG, Denton C, Fonseca C, Assassi S, Zhou X, Mayes MD, Simeón CP, Ortego-Centeno N, Castellví I, Carreira P; Spanish Scleroderma Group, Gorlova O, Beretta L, Santaniello A, Lunardi C, Hesselstrand R, Nordin A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Koeleman BP, Herrick A, Worthington J, Radstake TR, Martin J.

Arthritis Rheumatol. 2014 Dec;66(12):3521-3. doi: 10.1002/art.38870. No abstract available.

46.

Association of the HLA-DRB1 with scleroderma in Chinese population.

He D, Wang J, Yi L, Guo X, Guo S, Guo G, Tu W, Wu W, Yang L, Xiao R, Li Y, Chu H, Lai S, Jin L, Zou H, Reveille JD, Assassi S, Mayes MD, Zhou X.

PLoS One. 2014 Sep 3;9(9):e106939. doi: 10.1371/journal.pone.0106939. eCollection 2014.

47.

Autoimmune disease genetics 2013.

Niewold TB, Goulielmos GN, Assassi S.

J Immunol Res. 2014;2014:487643. doi: 10.1155/2014/487643. Epub 2014 Jul 6. No abstract available.

48.

Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis.

Chung L, Valenzuela A, Fiorentino D, Stevens K, Li S, Harris J, Hutchinson C, Assassi S, Beretta L, Lakshminarayanan S, Rodriguez-Reyna TS, Denton CP, Taillefer RG, Herrick AL, Baron M; Scleroderma Clinical Trials Consortium Calcinosis Working Group.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):425-30. doi: 10.1002/acr.22434.

49.

New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey.

Assassi S, Weisman MH, Lee M, Savage L, Diekman L, Graham TA, Rahbar MH, Schall JI, Gensler LS, Deodhar AA, Clegg DO, Colbert RA, Reveille JD.

Arthritis Rheumatol. 2014 Sep;66(9):2628-37. doi: 10.1002/art.38692.

50.

Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.

Wu M, Pedroza M, Lafyatis R, George AT, Mayes MD, Assassi S, Tan FK, Brenner MB, Agarwal SK.

Arthritis Rheumatol. 2014 Apr;66(4):1010-21. doi: 10.1002/art.38275.

Supplemental Content

Loading ...
Support Center